Semler Scientific, Inc.
NASDAQ•SMLR
CEO: Dr. Douglas Murphy-Chutorian M.D.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2014-02-21
Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.
Contact Information
2340-2348 Walsh Avenue, Suite 2344, Santa Clara, CA, 95051, United States
877-774-4211
Market Cap
$404.90M
P/E (TTM)
8.9
vs Industry 42.6
Dividend Yield (TTM)
--
52W High
$81.56
52W Low
$21.84
52W Range
4.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q2 2025 Data
Revenue
$8.22M-43.19%
4-Quarter Trend
EPS
$5.71+356775.00%
4-Quarter Trend
FCF
$446.00K-100.81%
4-Quarter Trend
Earnings Highlights
Key Highlights
No Data Available
Risk Factors
No Data Available
Outlook
No Data Available
Peer Comparison
Revenue (TTM)
$8.73B
$424.38M
$298.85M
Gross Margin (Latest Quarter)
91.0%
86.3%
TMCI79.7%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TOI | $437.08M | -67.3 | -1739.1% | 64.6% |
| TMCI | $425.16M | -8.8 | -46.8% | 34.0% |
| OMI | $418.28M | -0.3 | -278.2% | 11.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4-Quarter Revenue CAGR
-15.3%
Growth Under Pressure
4-Quarter Net Income CAGR
+128.5%
Significant Improvement in Profitability
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Reports
All Years
Form 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 4, 2025|Revenue: $8.22M-43.2%|EPS: $5.71+356775.0%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 13, 2025|Revenue: $8.84M-44.4%|EPS: $-6.74-865.9%N/AForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 28, 2025|Revenue: $56.29M-17.4%|EPS: $5.66+85.0%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 5, 2024|Revenue: $13.51M-17.2%|EPS: $0.80-2.4%BeatForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 6, 2024|Revenue: $14.47M-22.3%|EPS: $0.00-99.8%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 8, 2024|Revenue: $15.90M-12.7%|EPS: $0.88+18.9%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Mar 7, 2024|Revenue: $68.18M+20.3%|EPS: $3.06+43.7%BeatForm 10-Q - Q3 2023
Period End: Sep 30, 2023|Filed: Nov 13, 2023|Revenue: $16.32M+16.2%|EPS: $0.82+49.1%Beat